Developing a new class of autoimmune drugs
Welcome to Servatus
Servatus is an Australian biotechnology company researching and developing new primary and adjunct therapeutics for specific autoimmune, inflammatory and infectious conditions.
Established in 2012 and began operations in 2013. Servatus is an unlisted public company with its headquarters and operational facilities in Queensland, Australia. The company draws its name from Saint Servatius, a prominent church figure and diplomat during the 4th century AD, who was known for his reputed ability to heal various afflictions and ailments, including rheumatism.
With extensive preliminary research already completed, Servatus has now progressed to human clinical trials and advanced preclinical investigations for their LBP candidates and engineered proteins, respectively.
Leaders in live biotherapeutic drug development
Live Biotherapeutic Products (LBPs)
Servatus has isolated and characterised a number of unique microbial species and has conducted thorough preclinical research to formulate new medicines targeting autoimmune, inflammatory, and infectious conditions.
Human clinical trials to validate the clinical efficacy of these drugs are ongoing, with the ultimate goal of advancing safe and effective treatments for debilitating autoimmune conditions.
A pivotal endeavour involves creating pharmaceutical-grade live biotherapeutic agents derived primarily from bacterial microorganisms.
Novel Engineered Proteins
Further to their work on LBPs, Servatus is also engineering recombinant proteins to enhance their clinical efficacy, aiming for more potent treatments of autoimmune diseases while minimising adverse effects.
Servatus' engineered protein research is focused on enhancing specific therapeutic characteristics of select proteins to develop safe and effective treatments for immune-mediated inflammatory diseases. By targeting crucial protein characteristics, Servatus aims to enhance their clinical efficacy and supplement current drug therapies.
Servatus has pioneered the engineering of a modified protein selected for its inherent immune-modulating capabilities, with expectations of bolstering clinical efficacy and optimising commercial delivery.
State of the art biopharmaceutical manufacturing
New Drug Manufacturing Facilities
Servatus, in collaboration with an international partner, has established a cutting-edge production and research facility at Coolum Beach, Queensland, dedicated to manufacturing medical-grade biopharmaceuticals. The facility’s initial phase was completed in 2019, and features advanced laboratories and manufacturing suites, aswell as specialised departments in Research & Development, Product Development, Quality, Clinical Research and Production.
Having our own production facility empowers Servatus to meticulously manage every stage of the research, development and production pipeline processes. This enables us to ensure that our live biotherapeutic drug candidates (LBPs) meet our rigorous standards and specifications. Additionally, it eliminates the logistical uncertainties often associated with outsourcing.
New primary and adjunct treatment options for autoimmune conditions
Safe and Effective Treatments
Autoimmune diseases like rheumatoid arthritis and ulcerative colitis pose significant medical challenges, often poorly managed by existing medications and fraught with undesirable side effects. Servatus operates two distinct drug development platforms: Engineered proteins and live biotherapeutic products (LBPs), both aimed at addressing diseases and conditions that lack satisfactory treatment options.
As existing medications approach their limitations in delivering long-term efficacy and safety, exploring novel mechanisms of action offers the most promising avenue for advancing medical treatments in the future.